# AZD5335

Source: https://onco.cc/drugs/azd5335/  
OnCo record `azd5335` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

AZD5335 is an experimental antibody-drug conjugate from AstraZeneca in phase 3 trials for ovarian cancer, with its target not yet stated publicly.

## Summary

AZD5335 is an antibody-drug conjugate developed by AstraZeneca. Its molecular target is not stated in the ClinicalTrials.gov intervention record, and OnCo has not confirmed one from the sponsor's pipeline page. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, including the phase 3 study NCT07218809 (AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer), in ovarian cancer. The largest, NCT07218809, plans to enrol 1100 participants with primary completion expected 2028-11-17. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.

## Fields

- Kind: Treatment
- Status: phase-3
- Last checked: 2026-09-11
- Tags: pipeline; ctgov-ingest
- Modality: ADC
- Mechanism: Mechanism not stated in the ClinicalTrials.gov record or on the sponsor's pipeline page.

## Sources

- ClinicalTrials.gov: trials of AZD5335: https://clinicaltrials.gov/search?intr=AZD5335

## Connected records

- cancers: [Ovarian cancer](https://onco.cc/cancers/ovarian/)
- companies: [AstraZeneca](https://onco.cc/companies/astrazeneca/)
- trials: [AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer](https://onco.cc/trials/nct07218809/), [Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors](https://onco.cc/trials/nct05797168/)

---
JSON: https://onco.cc/api/v1/entities/azd5335.json